Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-१.४१%
१,०७६.१३
-१५.३८
-१.४१%
—१,०९१.५११,०९०.४०१,०९०.४०१,०७३.६९——
SIXC
Communications
SIXC
Communications
SIXC
-०.५५%
६०६.७४
-३.३७
-०.५५%
—६१०.११६१०.११६१०.२९६०६.१७——
SIXE
Energy
SIXE
Energy
SIXE
+०.८८%
१,२४८.८२
+१०.८४
+०.८८%
—१,२३७.९८१,२३७.८३१,२५२.४११,२२५.०३——
SIXI
Industrials
SIXI
Industrials
SIXI
-१.१७%
१,७२४.३६
-२०.३५
-१.१७%
—१,७४४.७११,७४०.९५१,७४७.२९१,७२१.५७——
SIXM
Financials
SIXM
Financials
SIXM
-०.७२%
६३५.५९
-४.५९
-०.७२%
—६४०.१८६३९.९२६४३.१९६३४.७३——
SIXR
Staples
SIXR
Staples
SIXR
-०.७६%
८४३.१५
-६.४३
-०.७६%
—८४९.५८८४५.२७८५१.६८८३९.४७——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.५५%
२१६.२९
-१.१९
-०.५५%
—२१७.४८२१७.४८२१८.१६२१५.५१——
SIXT
Technology
SIXT
Technology
SIXT
+०.०८%
३,२६३.४१
+२.७२
+०.०८%
—३,२६०.६९३,२७३.३६३,२८७.८१३,२४०.७८——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.३४%
९३९.२४
-३.२१
-०.३४%
—९४२.४५९३९.३९९४८.८०९३३.९८——
SIXV
Health care
SIXV
Health care
SIXV
-०.२९%
१,४६२.५६
-४.२४
-०.२९%
—१,४६६.८०१,४६४.७०१,४६७.१९१,४५८.३६——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-०.७१%
२,३८०.४०
-१७.१०
-०.७१%
—२,३९७.५०२,३९५.०३२,४१२.०१२,३७०.६४——
BIIB:NASDAQ
Biogen Inc
US$ १८७.२१
+०.०८%
(+०.१५) 1D
US$ १८७.२१
०.००% (०.००)
After hours
Closed: मे ४, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB...
Open
US$ १८६.२८
High
US$ १८७.५१
Low
US$ १८५.४४
Mkt. cap
२७.६४ अरब
Avg. vol.
१३.०७ लाख
Volume
६.२७ लाख
P/E ratio
२०.०९
52-wk high
US$ २०२.४१
52-wk low
US$ ११५.२८
EPS
US$ ९.३२
Beta
०.१९
Shares outstanding
१४.७६ करोड
No. of employees
८ हजार
News stories
From sources across the web
TipRanks
TipRanks
·
१३ घण्टा पहिले
Apellis Updates Executive Separation Plan Amid Biogen Merger
Simply Wall Street
Simply Wall Street
·
२१ घण्टा पहिले
How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal
MarketBeat
MarketBeat
·
२ दिन पहिले
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB
GuruFocus
GuruFocus
·
३ दिन पहिले
BIIB Maintains Rating by Citigroup -- Price Target Raised to $20
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees७.५ हजार
Founded१९७८
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websitebiogen.com
Last report
२०२६ अप्रिल २९
Fiscal Period
Q1 2026
Normalized EPS / Estimate
३.५७/ (२.८९ est.)USD
+२३.६१%beat
Revenue / Estimate
२.४८ अरब/ (२.२५ अरब est.)USD
+१०.३२%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
२.६५ अरब
२.५३ अरब
२.२८ अरब
२.४८ अरब
Cost of goods sold
९४.६२ करोड
५०.८६ करोड
४४.३४ करोड
६१.०२ करोड
Cost of revenue
९४.६२ करोड
५०.८६ करोड
४४.३४ करोड
६१.०२ करोड
Research and development expenses
-
४३.१८ करोड
५०.१० करोड
४८.२२ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५८.१३ करोड
५९.२८ करोड
६८.५२ करोड
६०.७३ करोड
Operating expense
७८.३७ करोड
१.२५ अरब
१.३९ अरब
१.३० अरब
Total operating expenses
१.७३ अरब
१.७६ अरब
१.८३ अरब
१.९१ अरब
Operating income
९१.५६ करोड
७७.८६ करोड
४४.७७ करोड
५६.७४ करोड
Other non operating income
-३३.०० लाख
१.५८ करोड
१.७४ करोड
-११.०० लाख
EBT including unusual items
७४.४० करोड
५५.७३ करोड
-५.६० करोड
३७.७७ करोड
EBT excluding unusual items
८६.१६ करोड
७४.८३ करोड
४२.३१ करोड
५३.०१ करोड
Income tax expense
१०.९२ करोड
९.०८ करोड
-७१.०० लाख
५.८२ करोड
Effective tax rate
१४.६८%
१६.२९%
१२.६८%
१५.४१%
Other operating expenses
७.५० करोड
८.७२ करोड
६.९९ करोड
७.४२ करोड
Net income
६३.४८ करोड
४६.६५ करोड
-४.८९ करोड
३१.९५ करोड
Net profit margin
२४.००%
१८.४०%
-२.१५%
१२.८९%
Earnings per share
५.४७
४.८१
१.९९
३.५७
Interest and investment income
३.२३ करोड
३.१६ करोड
३.७२ करोड
३.७९ करोड
Interest expense
-७.२६ करोड
-६.७४ करोड
-६.७५ करोड
-६.७६ करोड
Net interest expenses
-४.०३ करोड
-३.५८ करोड
-३.०३ करोड
-२.९७ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
१.११ अरब
९८.०८ करोड
६४.७९ करोड
७७.१८ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer